Product Information
METRONIDAZOLE 250 MG TABLET is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.1017 per EA under NDC 62332001671. Its NADAC has been published 504 times since Feb 8, 2017.
FDA first approved this application on Mar 13, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Metronidazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332001671
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METRONIDAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA079067FDA Approved
3/13/2009
TE Code
AB
On Market Since
12/1/2016
Pharmacological Classes
Price Statistics
The NADAC for METRONIDAZOLE 250 MG TABLET has been published 504 times since Feb 8, 2017, and over the history we have for it it has declined 59.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1017 per EA |
|---|---|
| All-time high | $0.2485 (Feb 15, 2017) |
| All-time low | $0.0623 (Dec 17, 2025) |
| 52-week high | $0.1070 |
| 52-week low | $0.0623 |
| Median price | $0.1234 |
| Average price | $0.1389 |
| Largest weekly change | +36.9% (May 22, 2019) |
| Weeks tracked | 504 |
| Tracking since | Feb 8, 2017 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metronidazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nitroimidazole Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METRONIDAZOLE 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METRONIDAZOLE 250 MG TABLET, manufactured by Alembic Pharmaceuticals Inc., is $0.1017 per EA (NDC 62332001671), effective Sep 30, 2026.
How has the price of METRONIDAZOLE 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for METRONIDAZOLE 250 MG TABLET has declined 59.1%. It has been tracked across 504 weekly CMS publications since Feb 8, 2017.
What are the highest and lowest recorded NADAC prices for METRONIDAZOLE 250 MG TABLET?
Since Feb 8, 2017, the NADAC for METRONIDAZOLE 250 MG TABLET has ranged from a low of $0.0623 (Dec 17, 2025) to a high of $0.2485 (Feb 15, 2017), with a median of $0.1234 per EA.
Are there cheaper alternatives to METRONIDAZOLE 250 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METRONIDAZOLE 250 MG TABLET, is $0.0970 per EA — about 5% below METRONIDAZOLE 250 MG TABLET.
Who manufactures METRONIDAZOLE 250 MG TABLET?
METRONIDAZOLE 250 MG TABLET (NDC 62332001671) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.